The efficacy of nuchal translucency with free beta-hCG, PAPP-A as a screening test for detection of chromosomal anomaly in the first trimester of pregnancy.
- Author:
Sung Joo KIM
1
;
Chang Mo KIM
;
Bong Sik MIN
;
Woo Seok SOHN
;
Jung Bae KANG
;
Pong Rheem JANG
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, Hallym University, Sacred Heart Hospital, Korea.
- Publication Type:Original Article
- Keywords:
Nuchal translucency;
Free beta-hCG;
PAPP-A;
Chromosomal anomaly
- MeSH:
Amniocentesis;
Biomarkers;
Chorionic Villi Sampling;
Down Syndrome;
Female;
Humans;
Mass Screening*;
Nuchal Translucency Measurement*;
Pregnancy;
Pregnancy Outcome;
Pregnancy Trimester, First*;
Pregnancy*;
Pregnancy-Associated Plasma Protein-A*;
Pregnant Women;
Turner Syndrome
- From:Korean Journal of Obstetrics and Gynecology
2001;44(6):1091-1096
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The aim of this study is to determine the efficacy of nuchal translucency in combination with free beta-hCG, PAPP-A in the first trimester screening for chromosomal anomaly in general population. METHODS: Between April 1998 and December 1999, we evaluated 263 pregnant women undergoing first trimester screening test for fetal chromosomal anomaly using nuchal translucency combined with free beta-hCG, PAPP-A. We confirmed the pregnancy outcomes through chorionic villi sampling, amniocentesis or term delivery. We excluded 15 pregnant women because of their obscure pregnancy outcomes. Statistical analysis was considered significant when P value was lower than 0.05. RESULTS: With a risk cut-off of 1 in 400, 24 pregnancies(9.7%) of 248 cases were screen positive and 224 pregnancies(90.3%) were screen negative. 2 cases of Down syndrome and 1 case of Turner syndrome were detected in screen positive group. No chromosomal anomalies were detected in screen negative group. CONCLUSION: In this study, 8.57% of false positive rate and 12.5% of positive predictive value were obtained in the first trimester screening for chromosomal anomaly using nuchal translucency and serum markers.
